Trial Profile
A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Nov 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Liver cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-240
- Sponsors Merck Sharp & Dohme Corp.
- 13 Sep 2022 Results reporting safety and efficacy data from KEYNOTE-240 after 4.5 years of extended follow-up presented at the 47th European Society for Medical Oncology Congress
- 13 Apr 2022 Results of prespecified meta-analysis of KEYNOTE-240 and KEYNOTE-394 obtaining a precise estimate of the pembro treatment effect, presented at the 113th Annual Meeting of the American Association for Cancer Research
- 08 Oct 2021 This trial has been completed in Germany and Denmark (End Date: 14 Sep 2021), according to European Clinical Trials Database record.